Navigation Links
Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
Date:9/27/2010

NEW YORK, Sept. 27 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the JMP Securities Healthcare Conference, being held at the New York Palace Hotel in New York City.  Mr. Bentsur's presentation is scheduled to take place tomorrow, Tuesday, September 28, 2010, at 1:00 p.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex™ (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel. 212.531.5965E-mail: lfischer@keryx.com
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
3. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
4. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
5. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
10. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ALSP, Inc. ... , MD as Consultant for Medical Affairs in preparation for ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased ... We look forward to working with an individual of such ... We look forward to drawing deeply on his broad experience ...
(Date:2/10/2016)... , Feb. 10, 2016 Intouch Solutions, a ... identified an industry-wide trend regarding the evolution of ... organizations to efficiently deliver compelling sales presentations via ... and another in 2015, Intouch uncovered that while ... devices and DSAs, many are not using them ...
(Date:2/10/2016)... HALLANDALE, Fla. , Feb. 9, 2016  Until ... sagging were surgery or liposuction. Thankfully, the FDA approved ... freezing them to death. Coolsculpting was originally approved in ... to the thighs and now the chin. With this ... Wellness Center can use a smaller applicator, the CoolMini, ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... As part of their 2015 end of year funding ... Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer research ... , “We are honored to support a promising young investigator from Dr. Lengyel’s lab ...
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel ... the Food Bank of Eastern Michigan last Friday in order to aid in the ... the Midwest to include a facility located in Clio, only 15 miles away from ...
(Date:2/10/2016)... ... 10, 2016 , ... InDemand Interpreting , a leading ... with Heart City Health Center to improve access to language services ... Health Center has provided the Elkhart community with access to high quality, affordable ...
(Date:2/10/2016)... ... , ... 10 Best Water is excited to announce a new ... that topped the list as a result of their commitment to offering clients creative, ... Tibet 5100, a top notch water company that specializes in providing the public with ...
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
Breaking Medicine News(10 mins):